Detection and functional portrayal of a novel class of dihydrotestosterone derived selective progesterone receptor modulators (SPRM)

[1]  M. Baker,et al.  Evolution of hormone selectivity in glucocorticoid and mineralocorticoid receptors , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  D. Edwards,et al.  Synthesis and antiprogestational properties of novel 17-fluorinated steroids , 2013, Steroids.

[3]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[4]  M. Baker,et al.  What are the physiological estrogens? , 2013, Steroids.

[5]  M. Laufgraben,et al.  Mifepristone for Management of Cushing's Syndrome , 2013, Pharmacotherapy.

[6]  Sara E. Nichols,et al.  A novel steroidal antiandrogen targeting wild type and mutant androgen receptors. , 2011, Biochemical pharmacology.

[7]  C. Telleria,et al.  Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression , 2011, BMC Cancer.

[8]  P. Bartůněk,et al.  Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling , 2011, Combinatorial chemistry & high throughput screening.

[9]  Vincent Laudet,et al.  Origin and evolution of the ligand-binding ability of nuclear receptors , 2011, Molecular and Cellular Endocrinology.

[10]  M. Baker,et al.  3D models of lamprey progesterone receptor complexed with progesterone, 7α-hydroxy-progesterone and 15α-hydroxy-progesterone , 2011, Steroids.

[11]  D. Surbek,et al.  Regulation of placental growth by aldosterone and cortisol. , 2010, Endocrinology.

[12]  M. Kampa,et al.  Testosterone membrane‐initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR , 2010, Molecular oncology.

[13]  J. Fagart,et al.  Met909 Plays a Key Role in the Activation of the Progesterone Receptor and Also in the High Potency of 13-Ethyl Progestins , 2009, Molecular Pharmacology.

[14]  J. Uitdehaag,et al.  The X-ray Structure of RU486 Bound to the Progesterone Receptor in a Destabilized Agonistic Conformation , 2009, The Journal of Biological Chemistry.

[15]  A. Sommer,et al.  Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  G. Kallergi,et al.  Membrane androgen receptor activation in prostate and breast tumor cells: Molecular signaling and clinical impact , 2009, IUBMB life.

[17]  David Thompson,et al.  Compound Profiling Using a Panel of Steroid Hormone Receptor Cell-Based Assays , 2008, Journal of biomolecular screening.

[18]  R. Winneker,et al.  A new generation of progesterone receptor modulators , 2008, Steroids.

[19]  C. Clarke,et al.  Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  B. Allolio,et al.  Mifepristone (RU 486) in Cushing's syndrome. , 2007, European journal of endocrinology.

[21]  Shawn P Williams,et al.  A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. , 2007, Molecular endocrinology.

[22]  Takashi Suzuki,et al.  5α‐Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production , 2007, International journal of cancer.

[23]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[24]  R. Sitruk-Ware.  Mifepristone and misoprostol sequential regimen side effects, complications and safety. , 2006, Contraception.

[25]  C. Russell,et al.  Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma , 2006, Cancer investigation.

[26]  Timothy M Willson,et al.  A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor*[boxs] , 2005, Journal of Biological Chemistry.

[27]  J. Cidlowski,et al.  The Origin and Functions of Multiple Human Glucocorticoid Receptor Isoforms , 2004, Annals of the New York Academy of Sciences.

[28]  M. Baker,et al.  Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors , 2004, Molecular and Cellular Endocrinology.

[29]  R. Steiner,et al.  A novel, high-affinity, fluorescent progesterone receptor antagonist. Synthesis and in vitro studies. , 2004, Bioconjugate chemistry.

[30]  I. Spitz.  Progesterone antagonists and progesterone receptor modulators: an overview , 2003, Steroids.

[31]  M. Bergström,et al.  Effects of androgens on aromatase activity and 11C‐vorozole binding in granulosa cells in vitro , 2003, Acta obstetricia et gynecologica Scandinavica.

[32]  C. Stournaras,et al.  The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors, which increase PSA secretion and modify actin cytoskeleton , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[34]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Foekens,et al.  Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer , 2000, Steroids.

[36]  W. Schoonen,et al.  Influence of the substitution of 11-methylene, Δ15, and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[38]  C. Hellal-Levy,et al.  Mechanistic aspects of mineralocorticoid receptor activation. , 2000, Kidney international.

[39]  J. Dhainaut,et al.  Effects of dobutamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock. , 1999, American journal of respiratory and critical care medicine.

[40]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[41]  E. Gurpide,et al.  Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. , 1997, Methods and findings in experimental and clinical pharmacology.

[42]  G. Teutsch,et al.  Non-steroidal antiandrogens: Synthesis and biological profile of high-affinity ligands for the androgen receptor , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  O. Jänne,et al.  A single-base substitution in exon 6 of the androgen receptor gene causing complete androgen insensitivity: the mutated receptor fails to transactivate but binds to DNA in vitro. , 1993, Human molecular genetics.

[44]  V. Jordan,et al.  Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells , 1993 .

[45]  P. Chambon,et al.  Progestin receptors: Isoforms and antihormone action , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  A. Albertini,et al.  Progestin regulation of alkaline phosphatase in the human breast cancer cell line T47D. , 1991, Cancer research.

[47]  E. Baulieu.  Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor , 1989 .

[48]  P. Munson,et al.  The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man. , 1988, The Journal of clinical endocrinology and metabolism.

[49]  B. Sun,et al.  Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486. , 1986, Endocrinology.

[50]  D. Philibert,et al.  RU 38486: a potent antiglucocorticoid in vitro and in vivo. , 1985, Journal of steroid biochemistry.

[51]  G. Chrousos,et al.  Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. , 1985, The Journal of clinical endocrinology and metabolism.

[52]  L C Murphy,et al.  Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. , 1985, Cancer research.

[53]  K. Pearce,et al.  Structure and function of the glucocorticoid receptor ligand binding domain. , 2004, Vitamins and hormones.

[54]  E. Gelmann,et al.  Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. , 2004, Molecular endocrinology.

[55]  B. Katzenellenbogen,et al.  Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. , 1999, Endocrinology.